Cargando…

Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population

Mostrar otras versiones (1)

Treatment of hepatitis C virus (HCV) infection for patients with human immunodeficiency virus (HIV) has improved with direct acting antivirals. However, outcomes among Black persons treated with ledipasvir/sofosbuvir (LDV/SOF) may be inferior to non-Blacks. We assessed responses to LDV/SOF in a coho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Banga, Jaspreet, Nizami, Sobia, Slim, Jihad, Nagarakanti, Sandhya, Portilla, Mario, Swaminathan, Shobha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2020
Materias:	4850
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7440318/ https://www.ncbi.nlm.nih.gov/pubmed/32176039 http://dx.doi.org/10.1097/MD.0000000000019140

Ejemplares similares

Hepatitis C Virus Treatment Response to Ledipasvir/Sofosbuvir Among Patients Co-Infected with HIV and HCV: Real-world Data in a Black Population
por: Banga, Jaspreet, et al.
Publicado: (2017)

Real-world Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Patients Coinfected with HCV and HIV-1
por: Ruane, Peter, et al.
Publicado: (2017)

HIV Coinfection Predicts Failure of Ledipasvir/Sofosbuvir in Treatment-Naïve Noncirrhotic Patients With HCV Genotype 1
por: Berenguer, Juan, et al.
Publicado: (2019)

Overall and cause-specific excess mortality in HIV-positive persons compared with the general population: Role of HCV coinfection
por: Alejos, Belén, et al.
Publicado: (2016)

Long-term follow-up of elite controllers: Higher risk of complications with HCV coinfection, no association with HIV disease progression
por: Stafford, Kristen A., et al.
Publicado: (2017)

Evaluation of Safety and Effectiveness of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch Followed by Ledipasvir/Sofosbuvir HCV Therapy in HIV–HCV Coinfection
por: Doyle, Mary-Anne, et al.
Publicado: (2019)

Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA: A MASTER cohort study
por: Focà, Emanuele, et al.
Publicado: (2016)

Real‐world safety and efficacy of sofosbuvir and ledipasvir for elderly patients
por: Tamai, Hideyuki, et al.
Publicado: (2018)

Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
por: Tadokoro, Tomoko, et al.
Publicado: (2017)

Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection
por: Nirei, Kazushige, et al.
Publicado: (2017)

The effectiveness of oral antiviral (Sofosbuvir/Ledipasvir) in treating children with HCV infection
por: Alkaaby, Ban Adil, et al.
Publicado: (2018)

Real World Experience of Sofosbuvir/Ledipasvir Therapy in HIV Patients Co-infected with HCV: A Retrospective Study
por: Al Obaidi, Mohanad, et al.
Publicado: (2017)

HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens
por: Huhn, Gregory D., et al.
Publicado: (2020)

Drug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care Cascade
por: Do, Albert, et al.
Publicado: (2015)

Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin
por: Bagaglio, Sabrina, et al.
Publicado: (2015)

Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
por: Lee, Soon Kyu, et al.
Publicado: (2022)

Hepatic fibrosis and immune phenotype vary by HCV viremia in HCV/HIV co-infected subjects: A Women's interagency HIV study
por: Desai, Seema N., et al.
Publicado: (2016)

Real-World Experience with Coformulated Ledipasvir and Sofosbuvir for HIV-Positive Patients with HCV Genotype 2 Infection: A Multicenter, Retrospective Study
por: Liou, Bo-Huang, et al.
Publicado: (2021)

Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection
por: Wang, Gary P., et al.
Publicado: (2018)

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany
por: Buggisch, Peter, et al.
Publicado: (2019)

Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report
por: d’Ettorre, Gabriella, et al.
Publicado: (2020)

Efficacy of an 8-week course of sofosbuvir and ledipasvir for the treatment of HCV infection in selected HIV-infected patients
por: Ogbuagu, Onyema, et al.
Publicado: (2018)

NKG2C(+) natural killer cell function improves the control of HBV replication in individuals with acute HIV infection coinfected with HBV
por: Song, Ting, et al.
Publicado: (2020)

Immune Compromise in HIV-1/HTLV-1 Coinfection With Paradoxical Resolution of CD4 Lymphocytosis During Antiretroviral Therapy: A Case Report
por: Rockwood, N., et al.
Publicado: (2015)

New-Onset Diabetes Mellitus With Exposure to Ledipasvir and Sofosbuvir
por: Premji, Resmi, et al.
Publicado: (2015)

Palisaded neutrophilic and granulomatous dermatitis associated with ledipasvir/sofosbuvir
por: Shenk, Mary Elizabeth Reed, et al.
Publicado: (2018)

Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States
por: Puenpatom, Amy, et al.
Publicado: (2017)

Early sofosbuvir-ledipasvir treatment for acute HCV infection induced severe immune thrombocytopenia – a case report
por: Alcazer, Vincent, et al.
Publicado: (2018)

Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4
por: Marascio, Nadia, et al.
Publicado: (2019)

Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment
por: Liu, Chun Jen, et al.
Publicado: (2021)

MELD Score Kinetics in Decompensated HIV+/HCV+ Patients: A Useful Prognostic Tool (ANRS HC EP 25 PRETHEVIC Cohort Study)
por: Gelu-Simeon, Moana, et al.
Publicado: (2015)

Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV
por: Rolle, Charlotte-Paige, et al.
Publicado: (2021)

Correlates of infection and molecular characterization of blood-borne HIV, HCV, and HBV infections in HIV-1 infected inmates in Italy: An observational cross-sectional study
por: Sanarico, Nunzia, et al.
Publicado: (2016)

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
por: Mushtaq, Saima, et al.
Publicado: (2020)

Relapse of HCV Genotype 1b Infection After Sofosbuvir/Ledipasvir Treatment Presenting as De Novo Cryoglobulinemic Vasculitis
por: Khan, Mohammad Qasim, et al.
Publicado: (2017)

Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2017)

A real-world, cross sectional study of oral lesions and their association with CD4 cell counts and HIV viral load in Yunnan, China
por: Shu, Wen, et al.
Publicado: (2020)

Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults
por: Li, Jin, et al.
Publicado: (2022)

No Evidence of an Association Between Efavirenz Exposure and Suicidality Among HIV Patients Initiating Antiretroviral Therapy in a Retrospective Cohort Study of Real World Data
por: Nkhoma, Ella T., et al.
Publicado: (2016)

Effectiveness of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in People Who Inject Drugs and/or Those in Opioid Agonist Therapy
por: Janjua, Naveed Z., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_irh5ai20prns02i9hpecsrjp3j